Compositions for enhancing sexual pleasure with reduced pharmaceutical load of pde5 inhibitor

A composition for increasing sexual pleasure in an adult male in need thereof, comprising:

• a dosage form selected from capsules, tablets, oral drops, infused edibles, infused food preparations, infused drink preparations, massage oils, lotions, gels, creams, lubricants, patches, and suppositories, the dosage form containing:
• a quantity of a single PDE5 inhibitor selected from up to 50 mg of sildenafil, up to 10 mg of tadalafil, up to 10 mg of vardenafil, or up to 100 mg of avanafil so to be no greater than 50% of a full prescription quantity or dose of the single PDE5 inhibitor for an adult male;
• and
• at least 5 mg, at least 6 mg, at least 8 mg, at least 9 mg, or at least 10 mg, of tetrahydrocannabinol so as to amplify the PDE5 inhibiting effect of the PDE5 inhibitor to at least 80% of the PDE5 inhibiting effect of the full prescription quantity or dose for an adult male,
• wherein the single PDE5 inhibitor and the cannabinoid component are effective in increasing sexual pleasure in the adult male in need thereof, including at least one of increased blood flow to erectile tissue, increased sexual desire, increased sexual arousal, increased sexual sensitivity, or increased strength of orgasm in the adult male.

A composition for increasing sexual pleasure in an adult female in need thereof, comprising:

• a dosage form selected from capsules, tablets, oral drops, infused edibles, infused food preparations, infused drink preparations, massage oils, lotions, gels, creams, lubricants, patches, and suppositories, the dosage form containing:
• a quantity of a single PDE5 inhibitor selected from up to 40 mg of sildenafil, up to 8 mg of tadalafil, up to 8 mg of vardenafil, or up to 80 mg of avanafil so to be no greater than 40% of a full prescription quantity of the single PDE5 inhibitor for an adult male;
• and
• at least 5 mg, at least 6 mg, at least 8 mg, at least 9 mg, or at least 10 mg, of tetrahydrocannabinol so as to amplify the PDE5 inhibiting effect of the PDE5 inhibitor to at least 80% of the PDE5 inhibiting effect of the full prescription quantity or dose for an adult male,
• wherein the single PDE5 inhibitor and the cannabinoid component are effective in increasing sexual pleasure in the adult female in need thereof, including at least one of increased blood flow to erectile tissue, increased sexual desire, increased sexual arousal, increased sexual sensitivity, or increased strength of orgasm in the adult female.